Genomic Data from Patients with Advanced Rare Cancers Treated with Pembrolizumab

Rare cancers lack effective evidence-based treatments despite contributing substantially to cancer-related mortality. The goal of this study is to identify molecular biomarkers associated with response to pembrolizumab in patients with advanced rare cancers.This dataset includes genomic profiling generated from patients enrolled in an investigator-initiated phase II basket trial of pembrolizumab.

Type: Exome Sequencing
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002182	This dataset comprises whole exome sequencing data and RNA-seq data of advanced rare cancer patients.	Illumina NovaSeq 6000	555